Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis

Psychopharmacology (Berl). 2020 Aug;237(8):2233-2255. doi: 10.1007/s00213-020-05563-3. Epub 2020 Jun 29.

Abstract

Rationale: Agonist-based pharmacologic intervention is an accepted approach in treatment of opioid and tobacco use disorders.

Objectives: We conducted a systematic review and meta-analysis to evaluate usefulness of an agonist approach as treatment of (psycho)stimulant use disorder (PSUD).

Methods: We reviewed PubMed/Medline, LILACS, and ClinicalTrials.gov databases searching for randomized, double-blind, placebo-controlled, parallel-design studies evaluating outcomes of individuals treated for cocaine- or amphetamine-type substance use disorder. We combined results of all trials that included the following prescription psychostimulants (PPs): modafinil, methylphenidate, or amphetamines (mixed amphetamine salts, lisdexamphetamine, and dextroamphetamine). The combined sample consisted of 2889 patients. Outcomes of interest included the following: drug abstinence (defined as 2-3 weeks of sustained abstinence and the average maximum days of consecutive abstinence), percentage of drug-negative urine tests across trial, and retention in treatment. We conducted random-effects meta-analyses and assessed quality of evidence using the GRADE system.

Results: Thirty-eight trials were included. Treatment with PPs increases rates of sustained abstinence [risk ratio (RR) = 1.45, 95% confidence interval (CI) = (1.10, 1.92)] and duration of abstinence [mean difference (MD) = 3.34, 95% CI = (1.06, 5.62)] in patients with PSUD, particularly those with cocaine use disorder (very low-quality evidence). Prescription amphetamines were particularly efficacious in promoting sustained abstinence in patients with cocaine use disorder [RR = 2.44, 95% CI = (1.66, 3.58)], and higher doses of PPs were particularly efficacious for treatment of cocaine use disorder [RR = 1.95, 95% CI = (1.38, 2.77)] (moderate-quality evidence). Treatment with prescription amphetamines also yielded more cocaine-negative urines [MD = 8.37%, 95% CI = (3.75, 12.98)]. There was no effect of PPs on the retention in treatment.

Conclusion: Prescription psychostimulants, particularly prescription amphetamines given in robust doses, have a clinically significant beneficial effect to promote abstinence in the treatment of individuals with PSUD, specifically the population with cocaine use disorder.

Keywords: Agonist; Amphetamine; Cocaine; Methamphetamine; Methylphenidate; Modafinil; Prescription psychostimulants; Psychostimulants; Replacement; Substance use disorders.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Amphetamine / therapeutic use
  • Central Nervous System Stimulants / therapeutic use*
  • Cocaine / therapeutic use
  • Double-Blind Method
  • Humans
  • Lisdexamfetamine Dimesylate / therapeutic use
  • Methylphenidate / therapeutic use
  • Modafinil / therapeutic use
  • Prescription Drugs / therapeutic use*
  • Randomized Controlled Trials as Topic / methods
  • Substance-Related Disorders / diagnosis*
  • Substance-Related Disorders / drug therapy*
  • Substance-Related Disorders / psychology
  • Treatment Outcome

Substances

  • Central Nervous System Stimulants
  • Prescription Drugs
  • Methylphenidate
  • Amphetamine
  • Cocaine
  • Modafinil
  • Lisdexamfetamine Dimesylate